Icatibant Medical Valley

Icatibant, the active ingredient in Icatibant Medical Valley, is a Bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients diagnosed with hereditary angioedema. GNH USA supplies Icatibant Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for the hereditary angioedema pathway, providing rapid symptom relief during attacks. - Acute hereditary angioedema: quickly reduces swelling and pain associated with an attack, improving airway safety and quality of life.

Icatibant may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or swelling at injection site: localized erythema or edema. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hypotension: sudden drop in blood pressure, potentially causing faintness. - Angioedema of the face or throat: paradoxical swelling despite treatment. - Thrombocytopenia: reduced platelet count observed in rare cases. - Severe injection site necrosis: tissue damage at the injection site.

Before using Icatibant, consider the following safety measures. - Assess severity of attack: ensure the episode warrants subcutaneous therapy. - Monitor for hypersensitivity: watch for signs of allergic reaction after injection. - Use with caution in cardiovascular disease: bradykinin blockade may affect blood pressure. - Avoid in known hypersensitivity to icatibant or its excipients. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence the bradykinin pathway or hemostasis.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and counteract icatibant's effect. - Neprilysin inhibitors: can elevate bradykinin, reducing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may affect bradykinin metabolism. - Other subcutaneous biologics: monitor injection site reactions. - Anticoagulants (e.g., warfarin): observe for altered bleeding risk.